Research output

Research output per year 2004 2016 2017 2018 2019 2020 2021 2022 2023 2024

• 256 Article
• 141 Letter
• 61 Review article
• 11 Comment/debate
• 15 More
  • 7 Editorial
  • 5 Chapter
  • 3 Short survey

Research output per year

Research output per year

Search results

• 2024

  Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders

  Lasho, T. & Patnaik, M. M., Feb 2024, In: Current Hematologic Malignancy Reports. 19, 1, p. 35-44 10 p.

  Research output: Contribution to journal › Review article › peer-review

  • Telomere 100%
  • Hematopoiesis 99%
  • Telomerase 29%
  • Telomere Shortening 17%
  • Preliminary Data 14%

• A Woman with Progressive Cough, Dyspnea, and Early Graying of Her Hair

  Hu, A., Patnaik, M. M. & Kelm, D. J., Mar 1 2024, In: Annals of the American Thoracic Society. 21, 3, p. 499-503 5 p.

  Research output: Contribution to journal › Article › peer-review

• Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

  Johnson, I. M., Karrar, O., Rana, M., Iftikhar, M., Chen, S., McCullough, K., Saliba, A. N., Al-Kali, A., Alkhateeb, H., Begna, K., Litzow, M., Hogan, W. J., Shah, M., Patnaik, M. M., Pardanani, A., Hermann, J., Tefferi, A. & Gangat, N., 2024, (Accepted/In press) In: British journal of haematology.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Acute Myeloid Leukemia 60%
  • Non-ST Elevated Myocardial Infarction 41%
  • Pericarditis 39%
  • Cardiomyopathies 30%

• Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management

  Patnaik, M. M. & Tefferi, A., 2024, (Accepted/In press) In: American journal of hematology.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Leukemia, Myelomonocytic, Chronic 100%
  • Risk Management 74%
  • Decitabine 25%
  • Molecular Models 25%
  • Hydroxyurea 23%

• EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant

  Baranwal, A., Mangaonkar, A., Shah, M. V., Al-Kali, A., Tefferi, A., Hogan, W. J., Litzow, M. R., Patnaik, M. M. & Alkhateeb, H. B., Apr 2024, In: Bone Marrow Transplantation. 59, 4, p. 558-560 3 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms

  WHO 5th Edition Classification Project, Feb 2024, In: Modern Pathology. 37, 2, 100397.

  Research output: Contribution to journal › Review article › peer-review

  • Lymphoid Tissue 100%
  • Global Health 90%
  • Neoplasms 29%
  • Myelodysplastic Syndromes 17%
  • Pathologists 15%

• Genetic Testing Goes Beyond Imaging and Histological Evaluation in Pleuroparenchymal Fibroelastosis

  Alrehaili, G., Kemppainen, J., Kalra, S., Pinto e Vairo, F., Moua, T., Yi, E. S., Ferrer, A., Patnaik, M. M. & Carmona, E. M., 2024, (Accepted/In press) In: Lung.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Telomere 100%
  • Genetic Testing 93%
  • Interstitial Lung Diseases 71%
  • Surface-Active Agents 67%
  • Pulmonary Fibrosis 44%

• Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases

  Tefferi, A., Abdelmagid, M., Al-Kali, A., Patnaik, M., Hogan, W. J., Begna, K., Gangat, N., Orazi, A., Chen, D., Reichard, K. K. & Pardanani, A., Jan 2024, In: American journal of hematology. 99, 1, p. 21-27 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Mast-Cell Leukemia 100%
  • Systemic Mastocytosis 86%
  • Survival 32%
  • Hematologic Neoplasms 27%
  • Neoplasms 10%

• Mast cell cytomorphology and treatment outcome in mast cell leukemia

  Tefferi, A., Pardanani, A., Al-Kali, A., Alkhateeb, H., McCullough, K., Patnaik, M., Hogan, W. J., Begna, K., Elliott, M. A., Khera, N., Palmer, J. M., Gangat, N., Kelemen, K., Orazi, A., Chen, D. & Reichard, K. K., Jan 2024, In: American journal of hematology. 99, 1, p. E5-E8

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia

  Gangat, N., McCullough, K., Abdelmagid, M., Karrar, O., Powell, M., Al-Kali, A., Alkhateeb, H., Begna, K., Mangaonkar, A., Saliba, A., Torghabeh, M. H., Litzow, M., Hogan, W., Shah, M., Patnaik, M., Pardanani, A., Badar, T., Foran, J., Palmer, J., Sproat, L., & 2 othersYi, C. A. & Tefferi, A., Jan 2024, In: Haematologica. 109, 1, p. 287-292 6 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope

  Elghetany, M. T., Patnaik, M. M. & Khoury, J. D., Feb 2024, In: Leukemia Research. 137, 107441.

  Research output: Contribution to journal › Review article › peer-review

  • Congenital Bone Marrow Failure Syndromes 100%
  • Back 58%
  • Neoplasms 18%
  • Hematologic Neoplasms 11%
  • Terminology 11%

• Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy

  Xie, Z., Lasho, T., Khurana, A., Ferrer, A., Finke, C., Mangaonkar, A. A., Ansell, S., Fernandez, J., Shah, M. V., Al-Kali, A., Gangat, N., Abeykoon, J., Witzig, T. E. & Patnaik, M. M., Feb 2024, In: Haematologica. 109, 2, p. 509-520 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Radioimmunotherapy 100%
  • Follicular Lymphoma 88%
  • Second Primary Neoplasms 82%
  • Hematopoiesis 78%
  • Mutation 15%

• Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome

  Pardanani, A., Tefferi, A., Al-Kali, A., Patnaik, M., Hogan, W. J., Begna, K., Elliott, M. A., Khera, N., Palmer, J. M., Gangat, N., Orazi, A., Kelemen, K., Reichard, K. K. & Chen, D., Jan 2024, In: American journal of hematology. 99, 1, p. E1-E4

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate

  Pritzl, S. L., Kusne, Y., Halfdanarson, T. R., Hobday, T., Sonbol, M. B., Kendi, A. T., Mangaonkar, A. A., Gangat, N., Shah, M. & Patnaik, M. M., Jan 2024, In: Leukemia Research. 136, 107434.

  Research output: Contribution to journal › Letter › peer-review

• Telomerase inhibition in haematological neoplasms—are we ready for primetime?

  Patnaik, M. M., Jan 20 2024, In: The Lancet. 403, 10423, p. 220-222 3 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients

  Gangat, N., Karrar, O., Iftikhar, M., McCullough, K., Johnson, I. M., Abdelmagid, M., Abdallah, M., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Mangaonkar, A., Saliba, A. N., Hefazi Torghabeh, M., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A., Badar, T., Murthy, H., & 6 othersForan, J., Palmer, J., Sproat, L., Khera, N., Arana Yi, C. & Tefferi, A., Feb 2024, In: American journal of hematology. 99, 2, p. 193-202 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Acute Myeloid Leukemia 60%
  • Genotype 45%
  • Mutation 35%
  • Survival 34%

• Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

  Karrar, O., Abdelmagid, M., Rana, M., Iftikhar, M., McCullough, K., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Elliott, M. A., Mangaonkar, A., Saliba, A., Hefazi Torghabeh, M., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A., Badar, T., Murthy, H., Foran, J., & 6 othersPalmer, J., Sproat, L., Khera, N., Arana Yi, C., Tefferi, A. & Gangat, N., Feb 2024, In: American journal of hematology. 99, 2, p. E63-E66

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients

  Nanaa, A., He, R., Foran, J. M., Badar, T., Gangat, N., Pardanani, A., Hogan, W. J., Litzow, M. R., Patnaik, M., Al-Kali, A. & Alkhateeb, H. B., Jan 2024, In: British journal of haematology. 204, 1, p. 171-176 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • GATA2 Deficiency 87%
  • Acute Myeloid Leukemia 40%
  • B-Cell Leukemia 29%
  • Myelodysplastic Syndromes 23%

• Venous and arterial thrombosis in patients with VEXAS syndrome

  Kusne, Y., Ghorbanzadeh, A., Dulau-Florea, A., Shalhoub, R., Alcedo, P. E., Nghiem, K., Ferrada, M. A., Hines, A., Quinn, K. A., Panicker, S. R., Ombrello, A. K., Reichard, K., Darden, I., Goodspeed, W., Durrani, J., Wilson, L., Olteanu, H., Lasho, T., Kastner, D. L., Warrington, K. J., & 15 othersMangaonkar, A., Go, R. S., Braylan, R. C., Beck, D. B., Patnaik, M. M., Young, N. S., Calvo, K. R., Casanegra, A. I., Grayson, P. C., Koster, M. J., Wu, C. O., Kanthi, Y., Patel, B. A., Houghton, D. E. & Groarke, E. M., 2024, (Accepted/In press) In: Blood.

  Research output: Contribution to journal › Article › peer-review

• VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management

  Koster, M. J., Lasho, T. L., Olteanu, H., Reichard, K. K., Mangaonkar, A., Warrington, K. J. & Patnaik, M. M., Feb 2024, In: American journal of hematology. 99, 2, p. 284-299 16 p.

  Research output: Contribution to journal › Review article › peer-review

  • Vacuoles 100%
  • Enzymes 51%
  • Azacitidine 41%
  • Allogeneic Cells 33%
  • Stem Cell Transplantation 32%

• VEXAS syndrome in a patient with DDX41 germline predisposition syndrome

  Kusne, Y., Lasho, T., Finke, C., Patnaik, M. M. & Badar, T., Jan 2024, In: Leukemia Research. 136, 107432.

  Research output: Contribution to journal › Letter › peer-review
• 2023

  Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  Abdallah, M., McCullough, K., Ilyas, R., Begna, K. H., Al-Kali, A., Litzow, M. R., Hogan, W. J., Mangaonkar, A., Alkhateeb, H., Shah, M. V., Elliott, M. A., Foran, J. M., Badar, T., Palmer, J. M., Yi, C. A., Sproat, L., Pardanani, A., Patnaik, M. M., Olteanu, H., Ketterling, R. P., & 2 othersTefferi, A. & Gangat, N., Dec 2023, In: Blood cancer journal. 13, 1, 35.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival

  Tefferi, A., Singh, A., Gangat, N., Al-Kali, A., Alkhateeb, H., Shah, M., Patnaik, M. S., Elliott, M. A., Hogan, W. J., Litzow, M. R., Wolanskyj-Spinner, A., Hook, C. C., Mangaonkar, A., Viswanatha, D., Chen, D., Pardanani, A., Begna, K. H. & Ketterling, R. P., Jan 2023, In: Haematologica. 108, 1, p. 245-249 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis

  Murthy, H. S., Zhang, M. J., Chen, K., Ahmed, S., Deotare, U., Ganguly, S., Kansagra, A., Michelis, F. V., Nishihori, T., Patnaik, M. M., Abid, M. B., Aljurf, M., Arai, Y., Bacher, U., Badar, T., Badawy, S. M., Ballen, K., Battiwalla, M., Beitinjaneh, A., Bejanyan, N., & 49 othersBhatt, V. R., Brown, V. I., Martino, R., Cahn, J. Y., Castillo, P., Cerny, J., Chhabra, S., Copelan, E., Daly, A., Dholaria, B., Perez, M. A. D., Freytes, C. O., Grunwald, M. R., Hashmi, S., Hildebrandt, G. C., Jamy, O., Joseph, J., Kanakry, C. G., Khera, N., Krem, M. M., Kuwatsuka, Y., Lazarus, H. M., Lekakis, L. J., Liu, H., Modi, D., Munshi, P. N., Mussetti, A., Palmisiano, N., Patel, S. S., Rizzieri, D. A., Seo, S., Shah, M. V., Sharma, A., Sohl, M., Solomon, S. R., Ulrickson, M., Ustun, C., van der Poel, M., Verdonck, L. F., Wagner, J. L., Wang, T., Wirk, B., Zeidan, A., Litzow, M. R., Kebriaei, P., Hourigan, C. S., Weisdorf, D. J., Saber, W. & Kharfan-Dabaja, M. A., 2023, In: Blood Advances. 7, 22, p. 7007-7016 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cell Transplantation 100%
  • Allogeneic Cells 99%
  • Dendritic Cells 82%
  • Bone Marrow 67%
  • Transplants 57%

• Allogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting: The Mayo Clinic Experience

  Singhal, S., Saadeh, S. S., Durani, U., Kansagra, A., Alkhateeb, H. B., Shah, M. V., Mangaonkar, A., Kenderian, S., Hashmi, S., Patnaik, M. V., Litzow, M. R. & Hogan, W. J., Mar 2023, In: Transplantation and Cellular Therapy. 29, 3, p. 183.e1-183.e6

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hematopoietic Stem Cell Transplantation 100%
  • Length of Stay 71%
  • Outpatients 70%
  • Hospital Mortality 44%
  • Inpatients 37%

• An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

  Stahl, M., Abdel-Wahab, O., Wei, A. H., Savona, M. R., Xu, M. L., Xie, Z., Taylor, J., Starczynowski, D., Sanz, G. F., Sallman, D. A., Santini, V., Roboz, G. J., Patnaik, M. M., Padron, E., Odenike, O., Nazha, A., Nimer, S. D., Majeti, R., Little, R. F., Gore, S., & 30 othersList, A. F., Kutchroo, V., Komrokji, R. S., Kim, T. K., Kim, N., Hourigan, C. S., Hasserjian, R. P., Halene, S., Griffiths, E. A., Greenberg, P. L., Figueroa, M., Fenaux, P., Efficace, F., DeZern, A. E., Della Porta, M. G., Daver, N. G., Churpek, J. E., Carraway, H. E., Brunner, A. M., Borate, U., Bennett, J. M., Bejar, R., Boultwood, J., Loghavi, S., Bewersdorf, J. P., Platzbecker, U., Steensma, D. P., Sekeres, M. A., Buckstein, R. J. & Zeidan, A. M., Jun 1 2023, In: Blood Advances. 7, 12, p. 2709-2714 6 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Antineutrophil cytoplasmic antibody–associated vasculitis and VEXAS syndrome: comment on the article by Muratore et al

  Koster, M. J., Ghaffar, U., Kermani, T. A., Patnaik, M. M., Go, R. S., Mangaonkar, A. A., Reichard, K. K., Olteanu, H. & Warrington, K. J., Aug 2023, In: Arthritis and Rheumatology. 75, 8, p. 1490-1492 3 p.

  Research output: Contribution to journal › Letter › peer-review

• A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression

  Al-Kali, A., Tibes, R., Atherton, P., Palmer, J., Alkhateeb, H. B., Patnaik, M., Begna, K., Gangat, N., Hashmi, S., He, R. & Litzow, M., Mar 2023, In: American journal of hematology. 98, 3, p. 472-480 9 p.

  Research output: Contribution to journal › Article › peer-review

  • 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 100%
  • Daunorubicin 87%
  • Cytarabine 78%
  • Acute Myeloid Leukemia 65%
  • Cell Transplantation 24%

• A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia

  Wang, Y. H., Yao, C. Y., Lin, C. C., Gurashi, K., Amaral, F. M. R., Bossenbroek, H., Jerez, A., Somervaille, T. C. P., Binder, M., Patnaik, M. M., Hou, H. A., Chou, W. C., Batta, K., Wiseman, D. H. & Tien, H. F., Apr 2023, In: British journal of haematology. 201, 2, p. 302-307 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelomonocytic, Chronic 100%
  • Stem Cells 50%
  • Genes 27%
  • Myelodysplastic Syndromes 11%
  • Acute Myeloid Leukemia 9%

• A TRIP11:: FLT3 gene fusion in a patient with myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions: a case report and review of the literature

  Venable, E. R., Gagnon, M. F., Pitel, B. A., Palmer, J. M., Peterson, J. F., Baughn, L. B., Hoppman, N. L., Greipp, P. T., Ketterling, R. P., Patnaik, M. S., Kelemen, K. & Xu, X., Feb 2023, In: Cold Spring Harbor Molecular Case Studies. 9, 1, a006243.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tyrosine Kinase Inhibitor 100%
  • Gene Fusion 81%
  • Eosinophilia 78%
  • Tyrosine 65%
  • Protein-Tyrosine Kinases 65%

• Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management

  Patnaik, M. M. & Tefferi, A., Apr 2023, In: American journal of hematology. 98, 4, p. 681-689 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 100%
  • Risk Management 62%
  • Leukocytosis 41%
  • Eosinophilia 20%
  • Allogeneic Cells 20%

• Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival

  Gangat, N., Kuykendall, A., Ali, N. A., Goel, S., Abdelmagid, M., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Mangaonkar, A., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A., Komrokji, R. & Tefferi, A., Jun 1 2023, In: Blood Advances. 7, 12, p. 2694-2698 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival

  Abdelmagid, M. G., Al-Kali, A., Begna, K. H., Hogan, W. J., Litzow, M. R., Fleti, F., Mangaonkar, A. A., Patnaik, M. S., Elliott, M. A., Alkhateeb, H., Shi, M., Howard, M. T., Reichard, K. K., Ketterling, R. P., Shah, M., Pardanani, A., Gangat, N. & Tefferi, A., Sep 2023, In: Haematologica. 108, 9, p. 2542-2545 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling

  Sandoval, L., Mohammed Ismail, W., Mazzone, A., Dumbrava, M., Fernandez, J., Munankarmy, A., Lasho, T., Binder, M., Simon, V., Kim, K. H., Chia, N., Lee, J. H., Weroha, S. J., Patnaik, M. & Gaspar-Maia, A., Jun 2023, In: Genes. 14, 6, 1245.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Small Nuclear RNA 100%
  • Small Cytoplasmic RNA 81%
  • Epigenomics 59%
  • Nonidet P-40 33%
  • Matched-Pair Analysis 29%

• Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

  Stahl, M., Bewersdorf, J. P., Xie, Z., Porta, M. G. D., Komrokji, R., Xu, M. L., Abdel-Wahab, O., Taylor, J., Steensma, D. P., Starczynowski, D. T., Sekeres, M. A., Sanz, G., Sallman, D. A., Roboz, G. J., Platzbecker, U., Patnaik, M. M., Padron, E., Odenike, O., Nimer, S. D., Nazha, A., & 28 othersMajeti, R., Loghavi, S., Little, R. F., List, A. F., Kim, T. K., Hourigan, C. S., Hasserjian, R. P., Halene, S., Griffiths, E. A., Gore, S. D., Greenberg, P., Figueroa, M. E., Fenaux, P., Efficace, F., DeZern, A. E., Daver, N. G., Churpek, J. E., Carraway, H. E., Buckstein, R., Brunner, A. M., Boultwood, J., Borate, U., Bejar, R., Bennett, J. M., Wei, A. H., Santini, V., Savona, M. R. & Zeidan, A. M., Nov 2023, In: Blood Reviews. 62, 101128.

  Research output: Contribution to journal › Review article › peer-review

  • Myelodysplastic Syndromes 100%
  • Neoplasms 28%
  • Value of Life 25%
  • Patient-Centered Care 20%
  • Risk Assessment 14%

• Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms

  Badar, T., Nanaa, A., Foran, J. M., Viswanatha, D., Al-Kali, A., Lasho, T., Finke, C., Alkhateeb, H. B., He, R., Gangat, N., Shah, M., Tefferi, A., Mangaonkar, A. A., Litzow, M. R., Ongie, L. J., Chlon, T., Ferrer, A. & Patnaik, M. M., Nov 2023, In: Haematologica. 108, 11, p. 3033-3043 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Neoplasms 100%
  • Psychological Latency Period 58%
  • Myelodysplastic Syndromes 43%
  • Hematologic Neoplasms 39%
  • Gene Frequency 37%

• Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study

  Pritzl, S. L., Gurney, M., Badar, T., Ferrer, A., Lasho, T., Finke, C., Mangaonkar, A., McCullough, K., Gangat, N., Fernandez, J., Al-Kali, A., Viswanatha, D., He, R., Foran, J. & Patnaik, M. M., Feb 2023, In: Leukemia Research. 125, 107007.

  Research output: Contribution to journal › Article › peer-review

• Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: The Mayo Clinic experience

  Katamesh, B., Nanaa, A., He, R., Viswanatha, D., Nguyen, P., Greipp, P., Bessonen, K., Gangat, N., Begna, K., Mangaonkar, A., Patnaik, M., Hogan, W. J., Tefferi, A., Litzow, M., Shah, M. V., Yi, C. A., Foran, J., Badar, T., Alkhateeb, H. B. & Al-Kali, A., Apr 25 2023, In: Blood Advances. 7, 8, p. 1351-1355 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Clinical impact of KIR haplotypes in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic hematopoietic stem cell transplantation

  Moyer, A. M., Hashmi, S. K., Kroning, C. M., Patnaik, M., Litzow, M., Gastineau, D. A., Hogan, W. J., Jacob, E. K., Kreuter, J. D., Wakefield, L. L. & Gandhi, M. J., 2023, In: Leukemia and Lymphoma. 64, 3, p. 671-678 8 p.

  Research output: Contribution to journal › Article › peer-review

  • KIR Receptors 100%
  • Unrelated Donors 87%
  • Hematopoietic Stem Cell Transplantation 74%
  • Haplotypes 65%
  • HLA-DPB1 antigen 28%

• Clonal Hematopoiesis: Origins and determinants of evolution

  Mendez, L. M. & Patnaik, M. M., Jun 2023, In: Leukemia Research. 129, 107076.

  Research output: Contribution to journal › Article › peer-review

  • Hematopoiesis 100%
  • Hematologic Neoplasms 46%
  • Neoplasm Genes 33%
  • Point Mutation 29%
  • Clone Cells 24%

• Clonal hematopoiesis of indeterminate potential: Overmedicalization or context dependant relevance?

  Patnaik, M. M., Oct 2023, In: Leukemia Research. 133, 107356.

  Research output: Contribution to journal › Editorial › peer-review

• Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations

  Mangaonkar, A. A. & Patnaik, M. M., Jun 2023, In: American journal of hematology. 98, 6, p. 951-964 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hematopoiesis 100%
  • Hematopoietic Stem Cells 20%
  • Chimeric Antigen Receptors 13%
  • Histocompatibility Antigens 12%
  • Gout 12%

• Clonal Hematopoiesis of Indeterminate Potential Is Associated with Coronary Microvascular Dysfunction in Early Nonobstructive Coronary Artery Disease

  Akhiyat, N., Lasho, T., Ganji, M., Toya, T., Shi, C. X., Chen, X., Braggio, E., Ahmad, A., Corban, M. T., Stewart, K., Fernandez, J., Xie, Z., Finke, C., Lerman, L. O., Patnaik, M. M. & Lerman, A., May 1 2023, In: Arteriosclerosis, thrombosis, and vascular biology. 43, 5, p. 774-783 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hematopoiesis 100%
  • Coronary Artery Disease 76%
  • Hematopoietic Stem Cells 22%
  • Alleles 16%
  • Adenosine 11%

• Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms

  Katamesh, B., Nanaa, A., He, R., Viswanatha, D., Nguyen, P., Greipp, P., Foran, J., Begna, K., Gangat, N., Patnaik, M., Tefferi, A., Litzow, M., Mangaonkar, A., Shah, M. V., Badar, T., Alkhateeb, H. B. & Al-Kali, A., Jan 2023, In: Annals of hematology. 102, 1, p. 211-212 2 p.

  Research output: Contribution to journal › Letter › peer-review

• CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases

  Ilyas, R., McCullough, K., Badar, T., Patnaik, M. M., Alkhateeb, H., Mangaonkar, A., Pardanani, A., Tefferi, A. & Gangat, N., Dec 2023, In: Blood cancer journal. 13, 1, 26.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1^st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

  Bewersdorf, J. P., Xie, Z., Bejar, R., Borate, U., Boultwood, J., Brunner, A. M., Buckstein, R., Carraway, H. E., Churpek, J. E., Daver, N. G., Porta, M. G. D., DeZern, A. E., Fenaux, P., Figueroa, M. E., Gore, S. D., Griffiths, E. A., Halene, S., Hasserjian, R. P., Hourigan, C. S., Kim, T. K., & 22 othersKomrokji, R., Kuchroo, V. K., List, A. F., Loghavi, S., Majeti, R., Odenike, O., Patnaik, M. M., Platzbecker, U., Roboz, G. J., Sallman, D. A., Santini, V., Sanz, G., Sekeres, M. A., Stahl, M., Starczynowski, D. T., Steensma, D. P., Taylor, J., Abdel-Wahab, O., Xu, M. L., Savona, M. R., Wei, A. H. & Zeidan, A. M., Jul 2023, In: Blood Reviews. 60, 101072.

  Research output: Contribution to journal › Review article › peer-review

  • Translational Medical Research 100%
  • Myelodysplastic Syndromes 99%
  • Education 55%
  • Neoplasms 28%
  • Animal Disease Models 16%

• Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings

  Hines, A. S., Mohandesi, N. A., Lehman, J. S., Koster, M. J., Cantwell, H. M., Alavi, A., Warrington, K. J., Mangaonkar, A. A., Go, R. S., Patnaik, M. M. & Sartori-Valinotti, J. C., Jul 2023, In: International journal of dermatology. 62, 7, p. 938-945 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Vacuoles 100%
  • Skin 51%
  • Enzymes 51%
  • Skin Diseases 45%
  • Panniculitis 44%

• Dedifferentiation of B-lymphoblastic leukemia/lymphoma with t(9;22) BCR::ABL1 to an undifferentiated neoplasm with strong keratin expression in a patient receiving blinatumomab

  Rozenova, K. A., Roden, A. C., Hartley, C., Peterson, J. F., Otteson, G. E., Al-Kali, A., Fuentes Bayne, H. E., Shah, M. V., Patnaik, M. S., King, R. L. & Larson, D. P., Mar 2023, In: Human Pathology Reports. 31, 300688.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Keratins 59%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 56%
  • Neoplasms 18%
  • Recurrence 13%
  • Second Primary Neoplasms 13%

• Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies

  Chlon, T. M. & Patnaik, M. M., Nov 2023, In: American journal of hematology. 98, 11, p. 1673-1676 4 p.

  Research output: Contribution to journal › Editorial › peer-review

• Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)

  Pinto e Vairo, F., Kemppainen, J. L., Vitek, C. R. R., Whalen, D. A., Kolbert, K. J., Sikkink, K. J., Kroc, S. A., Kruisselbrink, T., Shupe, G. F., Knudson, A. K., Burke, E. M., Loftus, E. C., Bandel, L. A., Prochnow, C. A., Mulvihill, L. A., Thomas, B., Gable, D. M., Graddy, C. B., Garzon, G. G. M., Ekpoh, I. U., & 43 othersPorquera, E. M. C., Fervenza, F. C., Hogan, M. C., El Ters, M., Warrington, K. J., Davis, J. M., Koster, M. J., Orandi, A. B., Basiaga, M. L., Vella, A., Kumar, S., Creo, A. L., Lteif, A. N., Pittock, S. T., Tebben, P. J., Abate, E. G., Joshi, A. Y., Ristagno, E. H., Patnaik, M. S., Schimmenti, L. A., Dhamija, R., Sabrowsky, S. M., Wierenga, K. J., Keddis, M. T., Samadder, N. J. J., Presutti, R. J., Robinson, S. I., Stephens, M. C., Roberts, L. R., Faubion, W. A., Driscoll, S. W., Wong-Kisiel, L. C., Selcen, D., Flanagan, E. P., Ramanan, V. K., Jackson, L. M., Mauermann, M. L., Ortega, V. E., Anderson, S. A., Aoudia, S. L., Klee, E. W., McAllister, T. M. & Lazaridis, K. N., Dec 2023, In: Journal of Translational Medicine. 21, 1, 410.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Undiagnosed Diseases 100%
  • Tertiary Healthcare 63%
  • Rare Diseases 62%
  • Genetic Counseling 49%
  • Genetic Testing 46%